Patents Assigned to Progeneer Inc.
  • Methods and genotyping panels for detecting alleles, genomes, and transcriptomes
    Patent number: 9994902
    Abstract: Disclosed are methods and genotyping panels for detecting alleles, genomes, and transcriptomes in admixtures of two individuals.
    Type: Grant
    Filed: May 1, 2015
    Date of Patent: June 12, 2018
    Assignee: Progenity, Inc.
    Inventors: Arnold R. Oliphant, Kurt A. Krummel, Haichuan Zhang, Andrew S. Katz
  • Treatment of Prader-Willi syndrome
    Patent number: 5006517
    Abstract: Prader-Willi Syndrome is alleviated by administering of a 3-oxo or hydroxy substituted 5-beta-androstan-17-one to an individual having the syndrome.
    Type: Grant
    Filed: July 24, 1989
    Date of Patent: April 9, 1991
    Assignees: Progenics, Inc., Long Island Jewish Medical Center
    Inventors: Leon Bradlow, Fred I. Chasalow
  • Increasing the bioavailability of alpha-etiocholanolone
    Patent number: 4871726
    Abstract: Methods and compositions are disclosed for inducing an incresed blood level of alpha-etiocholanolone in the body of a mammal in need of such treatments comprising administering to said mammal an amount of etiocholanedione effective to induce said increased blood level.
    Type: Grant
    Filed: July 28, 1987
    Date of Patent: October 3, 1989
    Assignee: Progenics, Inc.
    Inventors: Norman Applezweig, H. Leon Bradlow
  • Treatment of obesity and diabetes using sapogenins
    Patent number: 4680289
    Abstract: Obesity and diabetes obesity syndromes are treated with 5.beta.-sapogenin or .DELTA..sup.5 sapogenin.
    Type: Grant
    Filed: June 5, 1985
    Date of Patent: July 14, 1987
    Assignee: Progenics, Inc.
    Inventor: Norman Applezweig
  • Treatment of obesity, diabetes and other symptoms of hypercorticoidism using etiocholanolones
    Patent number: 4666898
    Abstract: Obesity, diabetes obesity syndromes and associated hypercorticoidism are treated with .alpha. and/or .beta.-etiocholanolone.
    Type: Grant
    Filed: December 19, 1984
    Date of Patent: May 19, 1987
    Assignees: Jackson Lab., Progenics, Inc.
    Inventors: Douglas L. Coleman, Norman Applezweig
  • Alkylated etiocholanolones and use as an anti-diabetic, anti-obesity and erythropoietic agent
    Patent number: 4602008
    Abstract: 16-Alkylated and 16-alkylated-7-hydroxy 5.beta.-androstan-3-ol-17-one, and the esters and ethers thereof, are used as an anti-diabetic, anti-obesity and erythropoietic agent in mammals.
    Type: Grant
    Filed: December 14, 1984
    Date of Patent: July 22, 1986
    Assignee: Progenics, Inc.
    Inventor: George Krsek
  • Manufacture of androstandione
    Patent number: 4507242
    Abstract: 5-.beta.-androstandione is produced in high yield by contacting androstendione with a palladium catalyst and thereafter recovering the 5-.beta.-androstandione thus produced.
    Type: Grant
    Filed: April 10, 1984
    Date of Patent: March 26, 1985
    Assignee: Progenics, Inc.
    Inventor: George Krsek
  • Treatment of diabetes and other symptoms of hypercorticoidism using a synergistic combination of etiocholanolones and estrogen
    Patent number: 4507289
    Abstract: Diabetes obesity syndromes and associated hypercorticoidism are treated with a synergistic combination of .alpha.- and/or .beta.-etiocholanolone and an estrogen.
    Type: Grant
    Filed: December 28, 1983
    Date of Patent: March 26, 1985
    Assignees: Progenics, Inc., The Jackson Laboratory
    Inventors: Douglas L. Coleman, Norman Applezweig